Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-b1355bc14a128fa4430d01fced9887b5"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-b1355bc14a128fa4430d01fced9887b5"/>
<resource>
<Composition>
<id value="composition-en-b1355bc14a128fa4430d01fced9887b5"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-b1355bc14a128fa4430d01fced9887b5"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-b1355bc14a128fa4430d01fced9887b5</b></p><a name="composition-en-b1355bc14a128fa4430d01fced9887b5"> </a><a name="hccomposition-en-b1355bc14a128fa4430d01fced9887b5"> </a><a name="composition-en-b1355bc14a128fa4430d01fced9887b5-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1392/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ervebo</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/19/1392/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpb1355bc14a128fa4430d01fced9887b5"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - ervebo"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Ervebo is and what it is used for</li><li>What you need to know before you or your child receives Ervebo</li><li>How Ervebo is given</li><li>Possible side effects</li><li>How to store Ervebo</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What ervebo is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What ervebo is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><ul><li>Ervebo is a vaccine for people who are 1 year of age and older.</li><li>Ervebo is given to protect people from getting Ebola virus disease caused by the Zaire Ebola virus, which is a type of Ebola virus. This vaccine will not protect against the other types of Ebola virus.</li><li>Because Ervebo does not contain the whole Ebola virus, it cannot give people Ebola virus disease. Your healthcare worker may recommend receiving this vaccine in an emergency involving the spread of Ebola virus disease. What is Ebola?</li><li>Ebola is a serious disease caused by a virus. If people get Ebola, it can kill them. People catch Ebola from people or animals who are infected with Ebola or who died from Ebola.</li><li>People can catch Ebola from blood and body fluids like urine, stools, saliva, vomit, sweat, breast milk, semen and vaginal fluids of people who are infected with Ebola virus.</li><li>People can also catch Ebola from things that have touched the blood or body fluids of a person or animal with Ebola (like clothes or objects in direct contact).</li><li>Ebola is not spread through the air, water or food. Your healthcare worker will talk to you and then together you can decide if you or your child should receive this vaccine.</li></ul></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take ervebo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take ervebo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not receive Ervebo if you:</p><ul><li>are allergic to Ervebo, rice, or any of the other ingredients of this vaccine (listed in section 6). You should not receive Ervebo if any of the above apply to you. If you are not sure, talk to your healthcare worker. Warnings and precautions This vaccine might not protect everyone who receives it and the length of time you are protected from Ebola by Ervebo is not known. Continue to follow your healthcare worker s recommendations to protect yourself from Ebola infection after you get this vaccine. Hand washing: Washing your hands correctly is the most effective way to prevent the spread of dangerous germs, like Ebola virus. It reduces the number of germs on the hands and so reduces their spread from person to person. Proper hand washing methods are described below;</li><li>Use soap and water when hands are soiled with dirt, blood, or other body fluids. There is no need to use antimicrobial soaps for washing hands.</li><li>Use alcohol-based hand sanitiser when hands are not dirty. Do not use alcohol-based hand sanitiser when hands are soiled with dirt, blood, or other body fluids. In an area affected by Ebola: While in an area affected by Ebola, it is important to avoid the following:</li><li>Contact with blood and body fluids (such as urine, faeces, saliva, sweat, vomit, breast milk, semen, and vaginal fluids).</li><li>Items that may have come in contact with an infected person s blood or body fluids (such as clothes, bedding, needles, and medical equipment).</li><li>Funeral or burial rituals that require handling the body of someone who died from Ebola.</li><li>Contact with bats, apes and monkeys or with blood, fluids and raw meat prepared from these animals (bushmeat) or meat from an unknown source.</li><li>Contact with semen from a man who had Ebola. You should follow safe sex practices until you know the virus is gone from the semen. In case of rash: If you get a rash where the skin is broken after receiving Ervebo, cover it until it heals. Put the used plasters and bandages in a sealed container, if possible, and throw them in the waste bin to make sure that people with a weak immune system or animals do not come into contact with the plasters and bandages. Taking care of children that have received Ervebo: For at least 6 weeks after children receive this vaccine, it is important that you wash your hands thoroughly after you have been in contact with blood or body fluids of vaccinated children. If possible clean soiled nappies with appropriate detergents/disinfectants or if using disposable nappies, seal them in double plastic bag and dispose of them in the household waste. Talk to your healthcare worker before you receive Ervebo if you: Have had allergic reactions to vaccines or medicines</li><li>If you have ever had an allergic reaction to a vaccine or medicine, talk to your healthcare worker before you receive this vaccine. Have a weak immune system If your immune system is weak (which means your body is less able to fight off diseases), you might not be able to receive Ervebo. You might have a weak immune system if:</li><li>you have HIV infection or AIDS,</li><li>you are taking certain medicines that make your immune system weak such as immunosuppressants or corticosteroids,</li><li>you have cancer or a blood problem that makes your immune system weak,</li><li>a member of your family has a weak immune system. If you think you might have a weak immune system, ask your healthcare worker if you should receive this vaccine. If you do get the vaccine and have a weak immune system, the vaccine may not work as well as in people with a normal immune system. Are in contact with vulnerable individuals Tell your healthcare worker if in the 6 weeks after you receive Ervebo you might be in close contact with or in the same household as:</li><li>babies who are less than 1 year old,</li><li>someone who may be pregnant or breast-feeding,</li><li>someone who has a weak immune system. This is because you could pass on the virus in the vaccine to them through your body fluids. Plan to donate blood</li><li>Do not donate blood for at least 6 weeks after you receive this vaccine. Are in contact with farm animals Make sure your blood or body fluids do not come into close contact with farm animals for at least 6 weeks after you receive this vaccine. This is because of a possibility that you could pass on the virus in the vaccine to the animals. Have a fever (high temperature)</li><li>If you have a fever (high temperature), you should talk to your healthcare worker before receiving Ervebo. The vaccination may have to be delayed until your fever is gone.</li><li>A minor infection such as a cold should not be a problem but talk to your healthcare worker before receiving Ervebo. Have a bleeding disorder or bruise easily</li><li>Tell your healthcare worker if you have a problem with bleeding or you bruise easily. Ervebo might make you bleed or bruise where the vaccine is injected. Testing for Ebola after you receive Ervebo</li><li>You may test positive for Ebola virus after you receive Ervebo. This does not mean that you have Ebola. Tell your healthcare worker that you have received Ervebo. Your healthcare worker might need to do another test. Children younger than 1 year of age If your child is under 1 year old, talk to your healthcare worker. It is not known if this medicine is safe and works in children under 1 year old. Other medicines and Ervebo Tell your healthcare worker if you are taking, have recently taken or might take any other medicines or vaccines. No studies have looked at how other medicines or vaccines and Ervebo might interact with each other. Use of Ervebo with other vaccines is not recommended. If you plan to receive blood or blood products Do not receive this vaccine at the same time that you get blood or blood products. Ervebo might not work as well if you get blood or blood products 3 months before or up to 1 month after vaccination. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your healthcare worker for advice before you receive this vaccine. They will help you decide if you should receive Ervebo. Do not become pregnant for 2 months after you receive Ervebo. Women who are able to become pregnant should use an effective method of birth control. It is not known if Ervebo will harm the mother or the unborn baby. It is also not known if it can pass to the baby through breast milk. If you might be in close contact with, or in the same household as someone who may be pregnant or breast-feeding during the 6 weeks after you receive Ervebo, tell your healthcare worker. This is because you could pass the vaccine to them through your body fluids. Ervebo contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium free .</li></ul></div>
</text>
</section>
<section>
<title value="3. How to take ervebo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take ervebo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Ervebo is given by a healthcare worker. It is given as a single injection (dose of 1 mL) in the top of the arm or the outside of the thigh. If you have any further questions on the use of this vaccine, ask your healthcare worker.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all vaccines, Ervebo can cause side effects, although not everybody gets them. Serious side effects: Serious side effects are rare. Get medical care right away if you or your child has symptoms of an allergic reaction, which may include:</p><ul><li>wheezing or trouble breathing,</li><li>swelling of the face, lips, tongue, or other parts of the body,</li><li>generalised itching, redness, flushing or itchy bumps on the skin. Other side effects in adults 18 years and older: Very common (may affect more than 1 in 10 people):</li><li>Headache,</li><li>Joint pain,</li><li>Muscle aches,</li><li>Fever,</li><li>Feeling tired,</li><li>Chills,</li><li>Pain, swelling, or redness at the injection site,</li><li>Eating less than usual,</li><li>Stomach pain. Common (may affect up to 1 in 10 people):</li><li>Nausea,</li><li>Skin rash,</li><li>Joint swelling,</li><li>Excessive sweating,</li><li>Feeling dizzy,</li><li>Mouth sores,</li><li>Itching at the injection site. Certain white blood cell counts can decrease below normal after vaccination but this decrease has not resulted in illness and the counts return to normal. Most side effects go away within a few days. Joint pain and swelling may last for weeks or months in some people. In some people joint pain and swelling may come back after initially going away. Side effects in children and adolescents 1 to 17 years of age: Very common (may affect more than 1 in 10 people):</li><li>Headache,</li><li>Eating less than usual,</li><li>Muscle aches,</li><li>Fever,</li><li>Feeling tired,</li><li>Chills,</li><li>Pain where your child got this vaccine,</li><li>Stomach pain. Common (may affect up to 1 in 10 people):</li><li>Joint pain,</li><li>Nausea,</li><li>Feeling dizzy,</li><li>Excessive sweating,</li><li>Mouth sores,</li><li>Crying,</li><li>Swelling or itching where your child got this vaccine. Uncommon (may affect up to 1 in 100 people):</li><li>Redness where your child got this vaccine. Tell your healthcare worker if you or your child gets any of the side effects listed above. Reporting of side effects If you get any side effects, talk to your healthcare worker. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</li></ul></div>
</text>
</section>
<section>
<title value="5. How to store ervebo"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store ervebo"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date which is stated on the vial label and the outer carton after EXP . The expiry date refers to the last day of that month.</li><li>Store and transport frozen at -80 C to -60 C.</li><li>After thawing, the vaccine should be used immediately. However, once thawed, the vaccine can be stored for up to 14 days at 2 C to 8 C before use. Discard the vaccine if it is not used by the end of 14 days. Once thawed, the vaccine cannot be re-frozen.</li><li>Upon removal from the freezer, the product should be marked with both the date that it was taken out of the freezer and also a new discard date (in place of the labelled expiry date).</li><li>Keep the vial in the outer carton in order to protect from light.</li><li>Do not use this vaccine if you notice particles in the liquid.</li><li>Do not throw away any medicines via wastewater or household waste. Ask your healthcare worker how to throw away medicines you no longer use. These measures will help protect the environment.</li></ul></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Ervebo contains The active substance is a living Vesicular Stomatitis Virus. The surface protein of the virus has been replaced with that of Zaire Ebola Virus (rVSV G-ZEBOV-GP). One dose (1 mL) contains: Ebola Zaire Vaccine (rVSV G-ZEBOV-GP1,2 live, attenuated) 72 million pfu3 1Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP) 2Produced in Vero cells 3pfu= plaque-forming units This product contains genetically modified organisms (GMOs). This vaccine contains a trace amount of rice protein. This vaccine contains less than 1 mmol (23 mg) of sodium per dose. The other excipients are recombinant human serum albumin, trometamol buffer, water for injections, hydrochloric acid, sodium hydroxide. What Ervebo looks like and contents of the pack</p><ul><li><p>Ervebo is a solution for injection.</p></li><li><p>Ervebo is a colourless to slightly brownish-yellow liquid.</p></li><li><p>Ervebo is available in a pack of 10 vials. Marketing Authorisation Holder Manufacturer Merck Sharp & Dohme B.V. Burgwedel Biotech GmbH Waarderweg Im Langen Felde 5 2031 BN Haarlem 30938 Burgwedel The Netherlands Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien MSD Belgium T l/Tel: +32(0)<a href="mailto:27766dpoc_belux@msd.com">27766dpoc_belux@msd.com</a> Lietuva UAB Merck Sharp & Dohme Tel.: <a href="mailto:+370.5.2780.msd_lietuva@merck.com">+370.5.2780.msd_lietuva@merck.com</a></p><pre><code> , </code></pre></li></ul><p>.: + 359 2 819 <a href="mailto:3info-msdbg@merck.com">3info-msdbg@merck.com</a> Luxembourg/Luxemburg MSD Belgium T l/Tel: +32 (0) <a href="mailto:27766dpoc_belux@msd.com">27766dpoc_belux@msd.com</a> esk republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 <a href="mailto:dpoc_czechslovak@merck.com">dpoc_czechslovak@merck.com</a> Magyarorsz g MSD Pharma Hungary Kft. Tel.: + <a href="mailto:36.1.888.5hungary_msd@merck.com">36.1.888.5hungary_msd@merck.com</a> Danmark MSD Danmark ApS Tlf: + 45 4482 <a href="mailto:4dkmail@merck.com">4dkmail@merck.com</a> Malta Merck Sharp & Dohme Cyprus Limited. Tel: 8007 4433 (+356 99917558) <a href="mailto:malta_info@merck.com">malta_info@merck.com</a> Deutschland MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) <a href="mailto:e-mail@msd.de">e-mail@msd.de</a> Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999(+31 23 5153153) <a href="mailto:medicalinfo.nl@merck.com">medicalinfo.nl@merck.com</a> Eesti Merck Sharp & Dohme O Tel.: +372 6144 <a href="mailto:msdeesti@merck.com">msdeesti@merck.com</a> Norge MSD (Norge) AS Tlf: +47 32 20 73 <a href="mailto:msdnorge@msd.no">msdnorge@msd.no</a></p><p>MSD . . . . . : +30 210 98 97 <a href="mailto:dpoc_greece@merck.com">dpoc_greece@merck.com</a> sterreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 <a href="mailto:dpoc_austria@merck.com">dpoc_austria@merck.com</a> Espa a Merck Sharp & Dohme de Espa a, S.A. Tel: +34 91 321 06 <a href="mailto:msd_info@merck.com">msd_info@merck.com</a> Polska MSD Polska Sp. z o.o. Tel.: <a href="mailto:+48.22.549.51.msdpolska@merck.com">+48.22.549.51.msdpolska@merck.com</a> France MSD France T l: +33 (0)1 80 46 40 Portugal Merck Sharp & Dohme, Lda Tel: +351 21 <a href="mailto:4465inform_pt@merck.com">4465inform_pt@merck.com</a> Hrvatska Merck Sharp & Dohme d.o.o. Tel: +385 1 66 11 <a href="mailto:croatia_info@merck.com">croatia_info@merck.com</a> Rom nia Merck Sharp & Dohme Romania S.R.L Tel: + 4021 529 29 <a href="mailto:msdromania@merck.com">msdromania@merck.com</a> Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 <a href="mailto:2998medinfo_ireland@msd.com">2998medinfo_ireland@msd.com</a> Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: <a href="mailto:+386.1.520.4msd.slovenia@merck.com">+386.1.520.4msd.slovenia@merck.com</a> sland Vistor hf. S mi: + 354 535 7Slovensk republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 <a href="mailto:58282dpoc_czechslovak@merck.com">58282dpoc_czechslovak@merck.com</a> Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) <a href="mailto:medicalinformation.it@msd.com">medicalinformation.it@msd.com</a> Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 <a href="mailto:info@msd.fi">info@msd.fi</a></p><p>Merck Sharp & Dohme Cyprus Limited : 800 00 673 (+357 22866700) <a href="mailto:cyprus_info@merck.com">cyprus_info@merck.com</a> Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 <a href="mailto:5700medicinskinfo@merck.com">5700medicinskinfo@merck.com</a> Latvija SIA Merck Sharp & Dohme Latvija Tel: <a href="mailto:+371.67364.msd_lv@merck.com">+371.67364.msd_lv@merck.com</a> United Kingdom (Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 <a href="mailto:2998medinfoNI@msd.com">2998medinfoNI@msd.com</a> This leaflet was last revised in MM/YYYY Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>. This leaflet is available in all EU/EEA languages on the European Medicines Agency website. <------------------------------------------------------------------------------------------------------------------------> The following information is intended for healthcare professionals only: Standard precautions when caring for patients with known or suspected Ebola disease Vaccination with Ervebo does not eliminate the necessity of standard precautions when caring for patients with known or suspected Ebola disease. All healthcare workers, and other ancillary providers who have been vaccinated, should not alter their practices with regard to safe injection, hygiene, and personal protective equipment (PPE) after vaccination. Standard precautions, as outlined by WHO, include the following:</p><ul><li>Basic hand hygiene</li><li>Respiratory hygiene</li><li>Use of PPE (to block splashes or other contact with infected materials)</li><li>Safe injection practices</li><li>Safe burial practices Healthcare workers caring for patients with suspected or confirmed Ebola virus should apply extra infection control measures to prevent contact with the patient s blood and body fluids and contaminated surfaces or materials such as clothing and bedding. When in close contact (within 1 metre) of patients with Ebola Virus Disease, healthcare workers should wear face protection (a face shield or a medical mask and goggles), a clean, non-sterile long-sleeved gown, and gloves (sterile gloves for some procedures). Laboratory workers are also at risk. Samples taken from humans and animals for investigation of Ebola infection should be handled by trained staff and processed in suitably equipped laboratories. Vaccine administrators should counsel vaccinees to continue to protect themselves with the following measures:</li><li>Hand washing</li><li>Avoid contact with blood and body fluids</li><li>Safe burial practices</li><li>Safe sex</li><li>Avoid contact with bats and non-human primates or blood, fluids and raw meat prepared from these animals (bushmeat) or meat from an unknown source. Instructions on the handling of the vaccine before administration</li><li>Ervebo is stored frozen at -80 C to -60 C and should be removed from the freezer and thawed in less than 4 hours until no visible ice is present. Do not thaw the vial in a refrigerator as it is not guaranteed that the vial will thaw in less than 4 hours. The thawed vial should then be gently inverted several times prior to withdrawal with the syringe.</li><li>After thawing, Ervebo should be used immediately; however, in-use stability data have demonstrated that once thawed, the vaccine can be stored for up to 14 days at 2 C to 8 C prior to use. At the end of 14 days, the vaccine should be used or discarded. Upon removal from the freezer, the product should be marked with both the date that it was taken out of the freezer and also a new discard date (in place of the labelled expiry date). Once thawed, the vaccine cannot be re-frozen.</li><li>Ervebo is a colourless to slightly brownish-yellow liquid. Discard the vaccine if particulates are present.</li><li>Ervebo should be administered intramuscularly. Do not inject the vaccine intravascularly. No data are available for administration via the subcutaneous or intradermal routes.</li><li>Ervebo should not be mixed in the same syringe with any other vaccines or medicinal products.</li><li>Withdraw the entire content of Ervebo from the vial using a sterile needle and syringe. The preferred injection site is the deltoid area of the non-dominant arm or in the higher anterolateral area of the thigh. Cover the injection site with gauze or bandage (e.g. any adhesive bandage or gauze and tape) that provides a physical barrier to protect against direct contact with vesicle fluid. The bandage may be removed when there is no visible fluid leakage.</li><li>Any unused vaccine or waste material should be disposed of in compliance with the institutional guidelines for genetically modified organisms or biohazardous waste, as appropriate. If breakage/spillage were to occur, disinfectants such as aldehydes, alcohols and detergents are proven to reduce viral infection potential after only a few minutes. If feasible, the waste liquid from eye washes should be collected and decontaminated before discarding into the drain.</li></ul></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpb1355bc14a128fa4430d01fced9887b5"/>
<resource>
<MedicinalProductDefinition>
<id value="mpb1355bc14a128fa4430d01fced9887b5"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpb1355bc14a128fa4430d01fced9887b5"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpb1355bc14a128fa4430d01fced9887b5</b></p><a name="mpb1355bc14a128fa4430d01fced9887b5"> </a><a name="hcmpb1355bc14a128fa4430d01fced9887b5"> </a><a name="mpb1355bc14a128fa4430d01fced9887b5-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1392/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Ervebo solution for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/19/1392/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Ervebo solution for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
